Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer-Reference-Cited by-同舟云学术

Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer

Published:1988-04 Issue:4 Volume:24 Page:733-736
ISSN:0277-5379
Container-title:European Journal of Cancer and Clinical Oncology
language:en
Short-container-title:European Journal of Cancer and Clinical Oncology

Author:

Cantwell Brian M.J.,Macaulay Valentine,Harris Adrian L.,Kaye Stanley B.,Smith Ian E.,Milsted Robert A.V.,Calvert A.Hilary

Publisher

Elsevier BV

Subject

Oncology

Reference6 articles.

1. A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice;Jones;Eur J Cancer Clin Oncol,1981

2. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homogolate and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate;Diddens;Cancer Res,1983

3. A phase I evaluation of the quinazole antifolate thymidylate synthease inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717;Calvert;J Clin Oncol,1986

4. Phase II study of a novel antifolate, N10-propargyl-5,8-dideazafolic acid (CB3717), in malignant mesothelioma;Cantwell;Cancer Treat Rep,1986

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying Candidates for Breast Cancer using Interactions of Chemicals and Proteins;Combinatorial Chemistry & High Throughput Screening;2018-02-13

2. Acetylenic antifolates as anticancer agents;Pteridines;2015-06-23

3. Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs;Mini-Reviews in Medicinal Chemistry;2010-11-01

4. Targeting thymidylate synthase by antifolate drugs for the treatment of cancer;Cancer Drug Design and Discovery;2008

5. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates;Investigational New Drugs;2006-01